Normal B lymphopoiesis is dependent on a close relationship between B-cell precursors and the bone marrow (BM) microenvironment. To further understand the mechanisms regulating the proliferation of the malignant counterpart of B-cell precursors, namely precursor-B acute lymphoblastic leukemia (ALL), we examined the adhesion to BM fibroblasts (BMF) of 1 9 cases of precursor-B ALL using a chromium labeling assay. Eleven of 19 cases showed greater than 10% binding to BMF (range 2.3% to 54.8%. mean 19.1 %). Binding was increased approximately twofold by preincubation of BMF with tumor necrosis factor and interleukin-4, which also resulted in upregulation of expression of vascular cell adhesion molecule-1 (VCAM-1) on BMF. The mechanism of attachment was investigated using murine monoclonal antibodies to leukocyte integrins, principally the beta, integrins VLA-4 and VLA-5, which were demonstrated to be present on most cases by flow cytometry. Statistically significant inhibition of adhesion was observed with antibodies to the beta, common subunit, VLA-HE MAJORITY of cases of acute lymphoblastic leuke-T mia (ALL) have immunophenotypic and genotypic properties that indicate derivation from early precursors of the B-lymphocyte lineage.',' Postnatally, early B lymphopoiesis occurs in the bone marrow (BM), and murine studies have shown that this process involves intimate contact with stromal cell^.^-^ A variety of cytokines derived from stromal cells, including interleukin-3 (IL-3), IL-7, stem cell factor, and probably other undefined molecules regulate the proliferation and differentiation of normal Bcell precursors"' and can induce short-term proliferation of precursor-B
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The precise regulatory influence of marrow stroma on longer-term growth and survival of ALL is uncertain, although recently it has been shown that contact with stroma can prevent apoptotic death of precursor-B ALL cells." The attachment of the leukemic cells with stromal elements presumably plays a central role in this process but has not been examined to date. Recent reports have identified a number of adhesion molecules on precursor-B ALL cells potentially capable of binding to ligands on stroma, including CD44, the VLA integnns VLA-4, VLA-5, and VLA-6, and the beta, integrin LFA-1.'2-'4 Ligands for CD44 include hyaluronic acid and fibronectin,I5-" both of which are present in BM stroma, whereas the VLA integrins bind to fibronectin or laminin.'82'9 We have recently demonstrated binding of precursor-B ALL cells and pre-B lymphoid cell lines to purified fibronectin, which is an effect mediated by both VLA-4 and VLA-5.I3 In addition to fibronectin, VLA-4 binds to vascular cell adhesion molecule-1 (VCAM-l), which is also expressed on BM fibroblasts (BMF)."22 To clarify the mechanism of attachment to the marrow microenvironment by precursor-B ALL cells, we examined the binding to marrow fibroblast layers. An important adhesion pathway is through VLA-4 and VLA-5, partly through stromal VCAM-1, although other ligands may also play a contributory role. 4 , and VLA-5, whereas little effect was seen with antibodies to VLA-6 or the beta, integrin subunit. Preincubation of fibroblasts with an antibody to VCAM-1 (a ligand of VLA-4) inhibited leukemic cell binding in the majority of cases, which was an effect also observed on cytokine-stimulated BMF. However, a minority of cases, as well as the pre-B lines NALM-6 and KM-3, showed no evidence of inhibition of adhesion with anti-VCAM-1 antibodies. Treatment of BMF with antifibronectin antibody alone had little effect on ALL adhesion and did not enhance the inhibitory effect of anti-VCAM-l . These data indicate that precursor-B ALL cells bind to BM stroma through the beta, integrins VLA-4 and VLA-5 and that this effect is partly mediated by VCAM-1 on stromal cells, although other undefined VLA ligands are also likely to be involved. Attachment of ALL cells to stroma is likely to play a key role in regulating the survival and growth of these cells through exposure to stromal cytokines. 0 1993 by The American Society of Hematology. 
MATERIALS AND METHODS
Leukemic Cells
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Adherent Cells
Normal human marrow cells were obtained from consenting donors for allogeneic BM transplantation. Briefly, light-density cells were separated by Ficoll-Paque density gradient centrifugation and cultured in McCoy's 5A culture medium (ICN Biomedicals) with 10% FCS, L-glutamine, and penicillin/streptomycin. Adherent BMF monolayers were passaged at least twice with trypsin-EDTA solution (Boehringer-Mannheim, Germany) before seeding into 96-well flat-bottom microtiter plates (Costar, Cambridge, MA) and used 48 hours later when confluent.
Antibodies and Flow Cytometry
The following MoAbs were purchased from commercial sources: P4G9 (CD49d) from Telios Pharmaceuticals (San Diego, CA); HP2/ 1 (CD49d) from Immunotech/Amac (Westbrook, ME); 4B4 (CD29) from Coulter Immunology (Hileah, FL); PHM2 (CD49e) from Silenus (Melbourne, Australia); and MHM23 (CDI 8) Dako (Carpinteria, CA). Two antibodies were kindly donated HP1/3 (CD49d) by Professor F. Sanchez-Madrid, Universidad Automna de Madrid, Spain; and GOH3 (CD49f) by Dr A. Sonnenberg, the Netherlands Red Cross Blood Transfusion Service. The specificity of MoAbs to VLA-4 is as follows: HP2/1 inhibits VLA-4 binding to both the CS-1 domain of fibronectin and VCAM-1, whereas HP 1/3 and P4G9 inhibit binding only to f i b r o n e~t i n .~~" *~~
We have previously demonstrated that PHM2 is an inhibitory VLA-5 antibody" equivalent in blocking activity to the commercially available antibody PID6 (CD49e, Telios Pharmaceuticals). Antibody WMD-7 is a murine IgG2b, raised in the authors' laboratory, which is reactive with a canine leukocyte antigen, but not with human cells, and was used as a negative control in adhesion assays.
For flow cytometry studies, leukemic cells were incubated with MoAbs (10 minutes, 20"C), washed twice, and then labeled with sheep antiserum to mouse immunoglobulin conjugated with fluorescein isothiocyanate (Silenus). After two further washes, cells were analyzed using an EPICS PROFILE I1 flow cytometer (Coulter, Hileah, FL) relative to appropriate isotype-matched negative control MoAbs. To block adhesion to components of the adherent layer, the following antibodies were used: 1G11 (anti-VCAM-I, Immunotech, Westbrook, ME), 4B9 (anti-VCAM-I; gift of Dr J.M. Harlan, Seattle, WA), and polyclonal antibody to human fibronectin (Telios Pharmaceuticals). Antibody 4B9 binds to Ig domain 1 of the VCAM-1 molecule,24 whereas the epitope of I G l l antibody on VCAM-I is unknown. Both antibodies are known to be inhibitory in functional assay^.^^.^^
Cell Adhesion Assay and Blocking Studies
For analysis of adhesion to BMF, leukemic blasts were labeled with 100 to 200 pCi 5 l-Cr04 (Amersham Australia, North Ryde) in Dulbecco's minimal essential medium (DMEM) (ICN Biomedicals) for 2 hours, with 5 X lo3 to IO4 counts per 5 X IO4 cells typically being incorporated. Then 5 X lo4 labeled leukemic cells in 100 pL DMEM were added to adherent fibroblast monolayers and plates centrifuged at lOOg for 5 minutes. After incubation for 2 hours at 37"C, wells were washed twice with phosphate-buffered saline (PBS), residual attached cells lysed with 2% sodium dodecylsulfate (SDS), and samples from each well were collected and counted on a gamma counter (Cobra Auto-Gamma; Packard, Canberra, Australia). Adhesion was calculated as follows:
The binding of cells to the extracellular matrix protein fibronectin was assessed using a previously described colorimetric assay." Briefly, 5 X IO4 kM-3 cells were added to microtiter wells precoated Abbreviation: NT, not tested.
Case numbers relate to those in Table 1 .
t Negative control antibody WMD-7.
$ Mean percentage adhesion of leukemic cells to BMF measured by chromium-labeling assay. Results of 2 or 3 experiments performed in triplicate. § P < ,005.
The within experiment variability is shown in parenthesis.
P < .05 compared with control.
with soluble fibronectin at 10 pg/mL with or without subsequent incubation with polyclonal antibody to fibronectin. After washing, cell binding was quantitated by staining with toluidine blue and optical absorbance at 630 nm measured. The effect of various blocking MoAbs on adhesion of cells to fibroblasts was assessed by preincubation of cells before the above adhesion assay. MoAbs to surface adhesion molecules were added in predetermined saturating concentrations to cells for 45 minutes at 4°C and cells added to fibroblasts without further washing. To block adhesion using antibodies to components of the adherent layer, antibodies to fibronectin and VCAM-1 (5 pg/mL) were incubated with the adherent layer for 30 minutes at 37°C before addition of the labeled leukemic cells.
Cytokine Stimulation of Stromal Cells
For analysis of the effects of cytokines on marrow stroma, BMF layers were incubated with recombinant human tumor necrosis factor a (TNF-(U 500 U/mL) or with recombinant human interleukin-4 (rhIL-4, 200 U/mL) (both Genzyme Corp, Boston, MA). These cytokines have been previously reported to upregulate the expression of VCAM-1 on marrow stroma.2'
Staining of Stromal Cells
A modification of a previously described enzyme-linked immunosorbent assay (ELISA) method was used to characterize antigen expression on normal human BMFF6 2 X lo4 fibroblasts/well were grown to confluence for 24 to 96 hours in 96-well culture plates (Costar). Wells were preincubated with 4% heat-inactivated normal rabbit serum for 20 minutes at 20°C to block potential nonspecific binding and then reacted with 50 pL of prediluted antibodies for 30 minutes at 20°C. Antibodies used were 1Gll (anti-VCAM-1) or Leu-54 (anti-ICAM-1, CD54; Becton Dickinson, Mountain View, CA), followed by peroxidase-conjugated anti-mouse Ig antiserum (Dakopatts, Glostrup Denmark), and a rabbit polyclonal antibody to human-fibronectin directly conjugated to peroxidase (Dakopatts). Wells were then incubated with peroxidase substrate (0.4 mmol/L tetramethylbenzidine dihydrochlorocitrate plus 0.05% H202 in 0.1 mol/L Na acetate/citric acid, pH 6).
Stained fibroblasts were then visually assessed under a micro- 
Statistical Analysis
Owing to the observed variability of adhesion between patient samples, and between experiments conducted on different days on the same patient samples, repeated measures analysis of variance was used to test for a difference between the percentage adhesion of negative control and that with each of the blocking antibodies. The within experiment variability of the percentage adhesion is the square root of the within day mean square error for that particular antibody.
RESULTS
Expression of Adhesion Molecules on Precursor-B ALL Cells
The pattern of adhesion molecule expression on the 19 cases of precursor-B ALL was similar to that reported previo~s l y . '~ The integnns VLA-4 and VLA-5 were expressed on over 50% of blast cells from most cases, as demonstrated by staining with MoAbs to VLA beta, subunit (CD29), VLA alpha, subunit (CD49d), alpha, (CD49e), whereas VLA-6 was detected on a lower percentage of cases using CD49f antibody (Table 1 ). In addition, the beta, integnn CD18 was expressed on 16 of 18 cases. cell types not being microscopically evident. Immunoperoxidase staining of BMF showed strong uniform expression ofCDI3, fibronectin, and VCAM-I and weak patchy staining for CDlO and intracellular adhesion molecule-I (ICAM-I, CD54). BMF were essentially negative for von Willebrand's factor and major histocompatibility complex (MHC) class 2 antigens.
Adhesion of ALL Cells to BMF
BMF used for adhesion assays consisted of confluent populations of monomorphic spindle-shaped cells, with other
The binding of precursor-B ALL cells labeled with 51-CrO, to BMF is shown in Table 2 . Relative to the total counts present in 5 X IO4 input cells, the mean binding of 19 cases was 19. I%, with a range of 2.3% to 54.8%. Three cases ( I , 2, and 3) showed less than 5% binding, and four cases (4, 5, 6, and 16) between 5% and 10%. Case 17 had a mean adhesion of 33%, but insufficient cells were available subsequently for blocking experiments. The three peripheral blood samples (cases 1 1, 15 , and 18) all showed relatively high binding to stroma (35% 33%, and 55%, respectively).
BRADSTOCK ET AL
There was an association between VLA-4 and VLA-5 expression on ALL blasts and their binding to BMF. Of 12 cases with greater than 75% cells positive for VLA-4, IO showed greater than 10% binding to BMF (Tables 1 and 2) ; cases 3 and 16 with a mean of 4.4% and 7.0% adhesion, respectively, were the only exceptions. In contrast, five of seven cases with less than 75% VLA-4+ cells had less than 10% binding to BMF. Of 12 cases with greater than 75% VLA-5+ cells, IO showed greater than 10% binding to BMF, whereas five of seven cases with less than 75% VLA-5+ cells had less than 10% binding. No association was seen, however, between the degree of binding and the following parameters: white blood cell count less than 50 X 109/L versus greater than 50 X 109/L; diagnosis versus relapse status: age younger than 15 years versus older than 15 years.
Analysis of Mechanism ofAdhesion ofALL Cells to BMF
Inhibition of adhesion molecirles on ALL cells. The mechanism of attachment of leukemic cells to BMF was analyzed using inhibitory MoAbs to leukocyte integrins in I I cases of ALL showing greater than 10% adhesion ( Table  2 ). Relative to negative control MoAb WMD-7, highly significant inhibition ofattachment was seen when blasts from all cases were preincubated with antibodies 4B4 (CD29, mean inhibition 76%), HP2/ I (CD49d, 63% inhibition), and P4G9 (CD49d, 50% inhibition). Antibodies HP1/3 (CD49d, 41%) and PHM-2 (CD49e, 56%) also significantly inhibited adhesion in 5 of6 and IO of I I cases, respectively. In contrast, with the exception of I case each, no inhibition was observed with antibodies GOH-3 (CD499 or MHM23 (CD18). Treatment of cells with both HP2/1 and PHM-2 resulted in a level ofinhibition ofbinding(74%) comparable to that observed with 4B4 (CD29) antibody alone.
Inhibition of ligands on BMF. The effect of blocking antibodies to VCAM-I and fibronectin, ligands of VLA-4 and VLA-5 on BMF, was next assessed. First, the effect of polyclonal antifibronectin antibody on the binding of pre-B ALL cells (KM-3) to fibronectin-coated plates is shown in Fig I. Complete inhibition was observed at a titer of 1:20, which was subsequently used for blocking studies on BMF. Next, the anti-VCAM antibodies 4B9 and I G l l were shown to inhibit the binding of peripheral blood lymphocytes to stimulated human umbilical vein endothelial cells (data not shown), as previously described?' In eight cases of ALL, marked inhibition of binding was again seen with preincubation of leukemic cells with MoAbs 4B4 (mean inhibition 75%), HP2/1 (55%), and PHM-2 (52%) ( Table 3) . MoAb IGll (anti-VCAM-I) at 5 pg/mL reduced ALL binding to BMF in six ofeight cases, with range of inhibition 16% to 45% (mean 27%, n = 6), although inhibition achieved statistical significance in only two cases. Treatment of BMF with polyclonal antibody to fibronectin reduced binding in three of eight cases (range 27% to 52% inhibition), but this was statistically significant in only two cases. However, incubation with both antifibronectin and 1 G 1 1 did not have an additional inhibitory effect compared with IG11 alone.
When BMF were incubated with TNF-a and IL-4, rapid upregulation of expression of VCAM-I was observed by 24 hours compared with unstimulated BMF, which persisted to 72 hours before declining (Fig 2) . In contrast, no increase in fibronectin was observed (data not shown). The attachment of leukemic cells to BMF treated with TNF and IL-4 for 48 hours is shown in Table 3 . Adhesion of ALL cells to stimulated BMF was enhanced (mean adhesion 36.4%) compared with untreated stromal cells (mean 2 1.4%), which represents a 70% increase in adhesion. Anti-integrin antibodies 4B4 (70%), HP211 (66%), and PHM-2 (47%) again markedly inhibited ALL binding to BMF. Antibody 1G11 significantly inhibited binding in three of eight cases, with a trend to inhibition in four other cases (range of inhibition 19% to 6270, mean 38%), whereas antifibronectin antibody did not significantly reduce adhesion in any case. The combination of 1 GI 1 and antifibronectin again had no additional effect over 1G11 antibody alone.
Data on the binding of the pre-B lymphoid leukemia cell lines KM-3 and NALM-6 to BMF are presented in Fig 3. Adhesion to unstimulated BMF was greater than that seen with cases of precursor-B ALL (KM-3 mean adhesion 63%; NALM-6 33%). Preincubation of cells with HP 2/1 antibody inhibited binding to BMF (KM-3 mean inhibition 42%; NALM-6 53%). In contrast, antibodies 1G11 and 4B9 (both anti-VCAM-I) and polyclonal antifibronectin antibody had no detectable inhibition of binding. Using BMF stimulated with TNF and IL-4, HP2/ 1 inhibited the adhesion o f m -3 (26%) and NALM-6 (56%), but again no effect of treating the stroma with 1G 1 1, 4B9, or antifibronectin was seen. Data points represent the mean of one experiment performed in quadruplicate wells -C 1 SD. *P < .02; **P < .001 for cytokinetreated wells versus medium alone.
ALL derived from marrow B-cell precursors express the leukocyte integrins VLA-4, VLA-5, VLA-6, and beta, integrin, and that the majority show binding to BMF monolayers in vitro. This adhesion was mediated by both VLA-4 and VLA-5, as demonstrated by inhibitory antibody studies. In most cases, the effect of the VLA-4 integrin involved interaction with stromal VCAM-1, although the degree of inhibition of adhesion with blocking antibodies to VCAM-1 was variable. In some ALL cases, anti-VCAM-1 had no detectable inhibitory effect on adhesion, whereas the adhesion of the two pre-B lines KM-3 and NALM-6 through VLA-4 to stroma also did not appear to be mediated by VCAM-1. For personal use only. on October 23, 2017. by guest www.bloodjournal.org From lular matrix of the marrow fibroblast monolayers used in this study to ALL adhesion is suggested by the blocking experiments with VLA-5 antibody and the incomplete inhibition seen with anti-VCAM-I. However, little effect on adhesion was seen using polyclonal antifibronectin treatment of stroma, which is consistent with previous observations on normal precursor-B cells29 and the UTMB-460 cell line.32 A similar phenomenon has been observed with marrow erythroid precursors, where adhesion to purified fibronectin was blocked by antifibronectin antibody, whereas this antibody had a weaker inhibitory effect on cell adhesion to stroma. 35 These observations indicate that fibronectin may be a functionally weak ligand in marrow stroma possibly due to the dominance of other receptor-ligand interactions (such as VLA-4/VCAM-l). Alternatively, antisera raised against pure fibronectin may not effectively block the interaction of integrins with fibronectin in extracellular matrix. Another explanation for the lack of blocking by VCAM-1 is that an alternative ligand (other than fibronectin) on stromal cells interacted with VLA-4 on leukemic cells. Evidence for such an alternative ligand for VLA-4 on human umbilical vein endothelial cells has recently been reported, where the anti-VCAM-1 MoAb 4B9 incompletely blocked the binding of the cell lines Ramos and SKW3, whereas anti-VLA-4 MoAb HP211 produced complete inhibition.22
In the present study, the beta, integrin family, although present on most cases of ALL, did not appear to be involved in adhesion to BMF, as judged by blocking experiments with CD18 MoAb (anti-beta, common subunit). In a previous study, the most common beta, integrin found on ALL blasts was CDI la,I3 which is the receptor for ICAM-I (CD54). Other investigators have demonstrated the involvement of beta, integrins in the binding of both normal myeloid progenitor cells and acute myeloid leukemia cells to marrow ~t r o m a .~' .~~ However, CDl8 MoAb did not inhibit the binding of normal human B-cell precursors to BMF,28,29 which suggests that this family is not important in primitive lymphoid cell adhesion to the marrow microenvironment. Alternatively, the low constitutive expression of ICAM-I on stromal fibroblasts may be a limiting factor for adhesion through this pathway.
Although the VLA-4 and VLA-5 integrins were demonstrated to mediate binding of ALL cells to BMF in this study, inhibition by beta, MoAb was incomplete, and other adhesion pathways are likely to be involved. A candidate for this role is CD44, which is ubiquitously expressed at high density on ALL b1a~ts.l~ CD44 is known to mediate binding of lymphocytes to a ligand, mucosal addressin, on high endothelial cells in mucosal vessels, but it is also known to bind to components of extracellular matrix, including hyaluronate, collagen type VI, and fibr~nectin.'~-'~,~' The precise role of CD44 in adhesion of ALL cells to marrow stroma was not investigated in this study because ofa lack of suitable inhibitory CD44 antibodies. However, previous studies have demonstrated inhibition of normal B lymphopoiesis in murine Whitlock-Witte cultures with CD44 antibodies suggesting either a role in adhesion or ~ignaling.~'
The significance of these adhesion studies is that contact with the marrow microenvironment is a key factor in the regulation of normal B lymphopoiesis allowing exposure of lymphoid precursors to regulatory cytokines secreted by specialized stromal cells. Similar regulatory mechanisms may influence both the survival and proliferation of precursor-B ALL cells after attachment to and localization in marrow microenvironment niches. The recent observations of prevention of apoptosis" and evidence of proliferation3' of precursor-B ALL cells in contact with various forms of marrow stroma are consistent with this hypothesis. A further effect of ALL adhesion via beta, integrins might be activation and stimulation through these molecules. In this regard, it is well recognized that both cross-linking or binding to natural ligands by integrins can induce signaling events in a variety of cells. 40 Recently, activation of VLA-4 was shown to induce tyrosine phosphorylation of a 1 IO-kD protein in NALM-6 cells suggesting interaction of VLA-4 with a tyrosine kinase in early B cells.41 Therefore, VLA integrins may act as a costimulant for growth of marrow precursor cells, including ALL blasts. This could be of considerable interest, as factors capable of inducing proliferation in precursor-B ALL have proved difficult to identify.
